Evidence map›Paper›PMID 37904590›Full record

ArticleActa obstetricia et gynecologica Scandinavica2024

Time trends in human papillomavirus prevalence and genotype distribution in vulvar carcinoma in Norway.

Christin Julia Meltzer-Gunnes, Agnes Kathrine Lie, Christine Genevieve Monceyron Jonassen, Anbjørg Rangberg, Camilla Furlund Nystrand, Milada Cvancarova Småstuen, Ingvild Vistad

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta obstetricia et gynecologica Scandinavica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Christin Julia Meltzer-GunnesDepartment of Obstetrics and Gynecology, Sorlandet Hospital HF, Kristiansand, Norway.ORCID 0000-0003-0578-4433
Agnes Kathrine LieDepartment of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Christine Genevieve Monceyron JonassenCenter for Laboratory Medicine, Ostfold Hospital HF, Fredrikstad, Norway.
Anbjørg RangbergCenter for Laboratory Medicine, Ostfold Hospital HF, Fredrikstad, Norway.
Camilla Furlund NystrandCenter for Laboratory Medicine, Ostfold Hospital HF, Fredrikstad, Norway.
Milada Cvancarova SmåstuenDepartment of Nursing and Health Promotion, Oslo and Akershus University College of Applied Sciences, Oslo, Norway.
Ingvild VistadDepartment of Obstetrics and Gynecology, Sorlandet Hospital HF, Kristiansand, Norway.ORCID 0000-0002-5262-6326
Østfold Hospital Trust · NOSørlandet Sykehus · NOOsloMet – Oslo Metropolitan University · NOOslo University Hospital · NO

Funding

Sorlandet Hospital Kristiansand
6 · The paper itself

Abstract

introductionApproximately 25%-43% of all vulvar carcinomas are associated with human papillomavirus (HPV). In many countries, vulvar carcinoma incidence rates are increasing, possibly due to greater HPV exposure. However, studies exploring changes in HPV prevalence and genotype distribution in vulvar carcinoma over time are scarce. Our aim was to evaluate time trends in HPV prevalence and genotype distribution in vulvar squamous cell carcinoma in an unselected, nationwide sample of Norwegian women. Further, we explored clinical and histopathological aspects in relation to HPV status and investigated whether HPV status was associated with survival. MATERIAL AND

methodsAll vulvar squamous cell carcinoma cases from 1970-1975 and 2000-2005 were extracted from the Cancer Registry of Norway and corresponding tissue blocks were retrieved. After detailed histology review, HPV testing was conducted using real-time TaqMan PCR. Overall survival rates were calculated using the Kaplan-Meier method. Multivariable Cox regression analysis was performed to estimate hazard ratios adjusted for age at diagnosis, stage and diagnostic period.

resultsHistological review was performed on 352 vulvar squamous cell carcinoma cases. We were able to obtain valid HPV analysis results for 282 cases, Overall, 29.8% (95% CI 24.5%-35.5%) of cases were high-risk HPV (hrHPV)-positive. When comparing the two periods, we found that the percentage of hrHPV-positive tumors increased significantly from 23% (95% CI 16.0%-31.4%) in 1970-1975 to 35.3% (95% CI 27.8%-43.3%) in 2000-2005 (P = 0.025). The predominant genotypes were HPV 16 (73%), HPV 33 (21%), and HPV 18 (6%), with similar distributions in both periods. In the more recent cohort, several additional genotypes were detected: HPV 6, 11, 39, 45, 52, 58 and 66 were found in smaller percentages, ranging from 1.8% to 3.6%. In univariate analysis, patients with HPV-positive tumors showed improved overall survival compared with patients with HPV-negative tumors (hazard ratio [HR] 0.65, 95% CI 0.48-0.86).

conclusionsThe prevalence of HPV in vulvar squamous cell carcinomas in Norway was significantly higher in 2000-2005 than in 1970-1975. The three predominant genotypes were HPV 16, 33 and 18 in both time periods. However, several other HPV genotypes have emerged over the last decades. HPV-positivity was associated with better overall survival.

Indexed as

Carcinoma, Squamous CellPapillomavirus InfectionsVulvar NeoplasmsFemaleGenotypeHuman Papillomavirus VirusesHumansNorwayPapillomaviridaePrevalencehuman papillomavirusprevalencesquamous cell carcinomasurvivalvulvar cancer

Identifiers

PMID37904590
PMCPMC10755140
OpenAlexW4388034059

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.